Patents by Inventor Audra L. Stinchcomb

Audra L. Stinchcomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10022366
    Abstract: Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: July 17, 2018
    Assignees: University of Maryland, Baltimore, University of Kentucky Research Foundation
    Inventors: Audra L. Stinchcomb, Priyanka Ghosh
  • Publication number: 20160074384
    Abstract: Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.
    Type: Application
    Filed: April 23, 2014
    Publication date: March 17, 2016
    Applicants: University of Maryland, Baltimore, University of Kentucky Research Foundation
    Inventors: Audra L. Stinchcomb, Priyanka Ghosh
  • Patent number: 8653271
    Abstract: The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: February 18, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Audra L. Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, Paul K. Kiptoo
  • Patent number: 8449908
    Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: May 28, 2013
    Assignee: Alltranz, LLC
    Inventors: Audra L. Stinchcomb, Buchi N. Nalluri
  • Patent number: 8435556
    Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: May 7, 2013
    Assignee: Alltranz, LLC
    Inventors: Audra L. Stinchcomb, Buchi N. Nalluri
  • Publication number: 20120202891
    Abstract: This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition.
    Type: Application
    Filed: April 29, 2009
    Publication date: August 9, 2012
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Audra L. Stinchcomb, Stan Lee Banks
  • Publication number: 20120202892
    Abstract: This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition.
    Type: Application
    Filed: April 20, 2012
    Publication date: August 9, 2012
    Applicant: University of Kentucky Research Foundation
    Inventors: Audra L. Stinchcomb, Stan Lee Banks
  • Publication number: 20120034293
    Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.
    Type: Application
    Filed: October 12, 2011
    Publication date: February 9, 2012
    Applicant: AllTranz Inc.
    Inventors: Audra L. Stinchcomb, Buchi N. Nalluri
  • Publication number: 20090291128
    Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.
    Type: Application
    Filed: July 29, 2009
    Publication date: November 26, 2009
    Applicant: AllTranz Inc.
    Inventors: Audra L. Stinchcomb, Buchi N. Nalluri
  • Publication number: 20090247619
    Abstract: This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition.
    Type: Application
    Filed: March 6, 2009
    Publication date: October 1, 2009
    Applicant: University of Kentucky
    Inventors: Audra L. STINCHCOMB, Stan Lee Banks
  • Publication number: 20090017102
    Abstract: The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.
    Type: Application
    Filed: October 18, 2007
    Publication date: January 15, 2009
    Applicant: University of Kentucky Research Foundation
    Inventors: Audra L. Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, Paul K. Kiptoo
  • Patent number: 7232460
    Abstract: An in-vivo method and apparatus is disclosed that comprises at least one sensor for determining changes in a human's an animal's body and reporting said changes outside the body. The sensor may be embedded in a sheath. The apparatus may be used to monitor chemical or physical changes in the body fluids. Alternatively, the apparatus may be used to monitor and regulate chemical or physical levels in humans and animals.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: June 19, 2007
    Assignee: Xillus, Inc.
    Inventors: Julian Van Erlach, Arlen L. Olsen, Jeffrey M. Smith, Laura B. Smith, Gerald E. Bender, Audra L. Stinchcomb, Denis P. Donnelly, James E. Peterson, Roger D. Whitmer, Gerald F. Dudding, Mark D. Scott
  • Patent number: 6569449
    Abstract: A composition, a method and an apparatus for transdermally delivering an effective amount of opioid antagonists derived from prodrugs for treatment of eating disorders, narcotic dependence and alcoholism. In addition, the present invention relates to a composition, a method and an apparatus for transdermally delivering an effective amount of an opioid and opioid antagonist derived from an opioid agonist and one of an opioid antagonist and a prodrug for treatment of pain.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: May 27, 2003
    Assignee: University of Kentucky Research Foundation
    Inventors: Audra L. Stinchcomb, Peter W. Swaan
  • Publication number: 20030032892
    Abstract: An in-vivo method and apparatus is disclosed that comprises at least one sensor for determining changes in a human's an animal's body and reporting said changes outside the body. The sensor may be embedded in a sheath. The apparatus may be used to monitor chemical or physical changes in the body fluids. Alternatively, the apparatus may be used to monitor and regulate chemical or physical levels in humans and animals.
    Type: Application
    Filed: April 25, 2002
    Publication date: February 13, 2003
    Inventors: Julian Van Erlach, Arlen L. Olsen, Jeffrey M. Smith, Laura B. Smith, Gerald E. Bender, Audra L. Stinchcomb, Denis P. Donnelly, James E. Peterson, Roger D. Whitmer, Gerald F. Dudding, Mark D. Scott
  • Publication number: 20020111551
    Abstract: A method for detecting body condition using nano and microdevices is disclosed. The microdevice or nanodevice is inserted into a fluid stream within a body, and used in detecting a bodily condition. The bodily condition may be myocardial infarction, stroke, sickle cell anemia, phlebitis, or a vascular aneurysm. The micro or nano device may be detected using electron paramagnetic resonance (EPR), electron spin resonance (ESR), and nuclear magnetic resonance (NMR).
    Type: Application
    Filed: November 30, 2000
    Publication date: August 15, 2002
    Inventors: Julian Van Erlach, Arlen L. Olsen, Jeffrey M. Smith, Laura B. Smith, Gerald E. Bender, Audra L. Stinchcomb, Denis P. Donnelly, Mark D. Scott, James E. Peterson, Robert S. Hirsch
  • Publication number: 20020111377
    Abstract: Disclosed is a method for relieving symptoms associated with illness or discomfort associated with the treatment of illness in a subject. The method includes providing a cannabinoid composition and delivering the cannabinoid transdermally to the subject. The cannabinoid composition used in this method includes at least one cannabinoid selected from the group consisting of &Dgr;9-THC, cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-&Dgr;9-THC, &Dgr;8-THC-11-oic acid, CP 55,940, and R(+)-WIN 55,212-2. Also disclosed is an occlusive body which includes an impermeable backing and a rate-controlling microporous membrane which together define a cavity in which a cannabinoid is disposed. Methods for increasing the concentration of cannabinoids or cannabinoid metabolites in a subject and for assessing the permeability of skin to cannabinoids are also described.
    Type: Application
    Filed: December 21, 2001
    Publication date: August 15, 2002
    Applicant: Albany College of Pharmacy
    Inventor: Audra L. Stinchcomb
  • Publication number: 20020098472
    Abstract: A method for inserting a microdevice or nanodevice into a body fluid stream is disclosed. The micro or nanodevice may be inserted into or external to a cell, e.g., a red blood cell. For insertion into the cell, techniques such as reversible osmotic lysis, electroporation, microfine needle injection, and particle gun injection may be used. For the external device, it may be chemically modified with an organo hydroxyl, such as poly (ethylene glycol), methoxypoly (ethylene glycol). Also, it may include a lipid anchor.
    Type: Application
    Filed: November 30, 2000
    Publication date: July 25, 2002
    Inventors: Julian Van Erlach, Arlen L. Olsen, Jeffrey M. Smith, Laura B. Smith, Gerald E. Bender, Audra L. Stinchcomb, Denis P. Donnelly, Mark D. Scott, James E. Peterson, Robert S. Hirsch
  • Publication number: 20020094515
    Abstract: A method and apparatus for attaching a microdevice or nanodevice to a biological member is disclosed. The biological member is one of a blood cell, lipid molecules, a liver cell, a nerve cell, a skin cell, a bone cell, a lymph cell, an endocrine cell, a circulatory cell, a muscle cell. The nanodevice or microdevice includes one of a diagnostic system, a transmitter, a receiver, a battery, a transistor, a capacitor, and a detector.
    Type: Application
    Filed: November 30, 2000
    Publication date: July 18, 2002
    Inventors: Julian Van Erlach, Arlen L. Olsen, Jeffrey M. Smith, Laura B. Smith, Gerald E. Bender, Audra L. Stinchcomb, Denis P. Donnelly, Mark D. Scott, James E. Peterson, Robert S. Hirsch